Description: CB1 Capital is an investment manager and advisor that specializes in the supply chain of cannabinoid-based wellness solutions, products and therapies that address a wide range of unmet medical conditions, or have commercial use-cases.
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.
Most cannabinoids are non-euphoric and many of them provide therapeutic benefits. What’s more, they interact with our ECS in ways that are beginning to reshape our understanding of health and wellness. The endocannabinoid system (ECS) is one of the most ubiquitous networks of receptors in the human body and a retrograde signaling system that helps to regulate neurotransmissions.
Science is teaching us that by targeting the right receptors with the right cannabinoids, a multitude of wellness indications, applications, and potentially groundbreaking medical breakthroughs are not only plausible—but probable.